GlassScriptPhysician profile
Garrick K Wang
NPI 1700099728
$15,023.98
in general payments reported to CMS, 2019-2025
22 companies · $2,283 in 2025
The $2,283 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $1,783 · 2021: $2,197 · 2022: $2,352 · 2023: $2,331 · 2024: $2,310 · 2025: $2,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,924.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,405.16 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $1,980.02 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,721.53 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $1,438.62 | 2023-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $1,357.82 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $1,113.63 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $889.58 | 2019-2022 | |
| Alkermes, INC. | $864.91 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $602.84 | 2019-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $543.81 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $405.03 | 2022-2025 | Ingrezza |
| Almatica Pharma LLC | $355.03 | 2021-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $258.52 | 2023-2025 | Uzedy, Austedo Xr |
| Jazz Pharmaceuticals INC. | $203.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $198.74 | 2019-2024 | Invega Sustenna, Invega |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $157.42 | 2023-2024 | Quviviq |
| Shire North American Group INC | $141.69 | 2019 | |
| Indivior INC. | $137.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $100.32 | 2019-2023 | Belsomra |
| E.R. Squibb & Sons, L.L.C. | $69.12 | 2025 | Cobenfy |
| Bausch Health US, LLC | $57.17 | 2022-2023 | Aplenzin |
| Eisai INC. | $21.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrick Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.